Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy

MLA

Angela Tong, et al. “Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.” Circulation, vol. 143, no. 8, Dec. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....918f38bdf28a8a4261e8be3b2b2a877d&authtype=sso&custid=ns315887.

APA

Angela Tong, Chintan V. Dave, Elisabetta Patorno, Allison B. Goldfine, Seoyoung C. Kim, & Robert J. Glynn. (2020). Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy. Circulation, 143(8).

Chicago

Angela Tong, Chintan V. Dave, Elisabetta Patorno, Allison B. Goldfine, Seoyoung C. Kim, and Robert J. Glynn. 2020. “Risk of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Addition of SGLT2 Inhibitors Versus Sulfonylureas to Baseline GLP-1RA Therapy.” Circulation 143 (8). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....918f38bdf28a8a4261e8be3b2b2a877d&authtype=sso&custid=ns315887.